Effect of N ‐acetyl cysteine in children with metabolic dysfunction‐associated steatotic liver disease—A pilot study
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12312 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von P Babu Balagopal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Pediatrics, Nemours Children's Health, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Acetylcysteine, Non-alcoholic Fatty Liver Disease, Oxidative Stress, Insulin Resistance. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: American Diabetes Association, Nemours Biomedical Research.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), and its sequelae of more severe forms such as metabolic dysfunction‐associated steatohepatitis (MASH) is rapidly increasing in children with the rise in obesity. Successful and sustainable treatments for MASLD are lacking in children. We determined the therapeutic effect of N ‐acetyl cysteine (NAC) on biomarkers of oxidative stress, inflammation and insulin resistance (IR), liver enzymes, liver fat fraction (LFF) and liver stiffness (LS) in children with obesity and biopsy‐confirmed MASLD.
Methods
Thirteen children ( n = 13; age: 13.6 ± 2.8 years; NAS score >2) underwent a double‐blind, placebo‐controlled trial of NAC (either 600 or 1200 mg NAC/day) or placebo for 16 weeks. Measurements included LFF (magnetic resonance imaging), LS (ultrasound elastography), and body composition. Erythrocyte glutathione (GSH), liver enzymes, insulin, glucose, adiponectin, high‐sensitivity c‐reactive protein (hs‐CRP), and interleukin‐6 (IL‐6) were also measured. homeostasis model assessment for insulin resistance (HOMA‐IR) was calculated.
Results
Sixteen‐week NAC treatment improved (baseline adjusted between‐group p < .05 for all) markers of inflammation (IL‐6 and hs‐CRP), oxidative stress (GSH), and IR (HOMA‐IR) and reduced liver enzymes, LFF and LS. Body weight and body composition did not show beneficial changes.
Conclusions
Sixteen‐week NAC treatment was well tolerated in children with obesity and MASLD and led to improvements in oxidative stress, inflammation and IR and liver outcomes. The results from this pilot study support further investigation of NAC as a therapeutic agent in children with MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Pediatrics, Nemours Children's Health, Jacksonville, Florida, USA.
- Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Department of Pediatrics, University of South California, Los Angeles, California, USA.
- Department of Pediatrics, Nemours Children's Health, Wilmington, Delaware, USA.
ORCID-Profile: P Babu Balagopal
Förderung
- American Diabetes Association
- Nemours Biomedical Research
Zitieren
APA
Babu Balagopal, P., Kohli, R., Uppal, V., Averill, L., Shah, C., McGoogan, K., Di Guglielmo, M., Goran, M., & Hossain, M. J. (2024). Effect of N ‐acetyl cysteine in children with metabolic dysfunction‐associated steatotic liver disease—A pilot study. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12312
Vancouver
Babu Balagopal P, Kohli R, Uppal V, Averill L, Shah C, McGoogan K, et al. Effect of N ‐acetyl cysteine in children with metabolic dysfunction‐associated steatotic liver disease—A pilot study. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12312
BibTeX
@article{BabuBalagopal2024,
author = {Babu Balagopal, P and Kohli, Rohit and Uppal, Vikas and Averill, Lauren and Shah, Chetan and McGoogan, Katherine and Di Guglielmo, Matthew and Goran, Michael and Hossain, Md Jobayer},
title = {Effect of N ‐acetyl cysteine in children with metabolic dysfunction‐associated steatotic liver disease—A pilot study},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12312}
}
EUVIMED